Objective and subjective measures of dalfampridine efficacy in clinical practice

BACKGROUND: Multiple sclerosis affects mobility in over 80% of patients. Dalfampridine is the only approved treatment for walking impairment in multiple sclerosis. We assessed dalfampridine utilization in our practice and investigated response using timed 25 foot walk (T25FW) improvement and a patie...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Mult Scler J Exp Transl Clin
Asıl Yazarlar: Klineova, Sylvia, Farber, Rebecca, Friedman, Joshua, Farrell, Colleen, Lublin, Fred D, Krieger, Stephen
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: SAGE Publications 2018
Konular:
Original Research Paper
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6077903/
https://ncbi.nlm.nih.gov/pubmed/30090641
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2055217318786742
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller